Entero Healthcar

INR
1,111.60
17.4 (1.59%)
BSENSE

Mar 20

BSE+NSE Vol: 54.58 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

54.58 k (-32.23%) Volume

Shareholding (Dec 2025)

FII

5.14%

Held by 63 FIIs

DII

6.17%

Held by 11 DIIs

Promoter

52.42%

Has Entero Healthcar declared dividend?

06-Jun-2025

No Dividend History Available

Who are the peers of the Entero Healthcar?

16-Jul-2025

Entero Healthcare's peers include A B Lifestyle, Medplus Health, Aditya Vision, Khemani Distrib., M K Exim India, Purple United, Osia Hyper Retail, Purv Flexi, and Silgo Retail. Entero Healthcare shows average management risk and good growth, with a 1-year return of 4.75%, lower than Medplus Health's 38.34% but higher than Aditya Vision's -19.70%.

Peers: The peers of Entero Healthcar are A B Lifestyle, Medplus Health, Aditya Vision, Khemani Distrib., M K Exim India, Purple United, Osia Hyper Reta., Purv Flexi, and Silgo Retail.<BR><BR>Quality Snapshot: Excellent management risk is observed at Aditya Vision, Khemani Distrib., M K Exim India, and Purple United, while Average management risk is found at Entero Healthcar and the rest. Good growth is noted at Medplus Health, Aditya Vision, Khemani Distrib., M K Exim India, Purple United, and Osia Hyper Reta., while Entero Healthcar shows excellent growth and the rest have below average growth. For capital structure, excellent ratings are seen at Khemani Distrib. and M K Exim India, good at Entero Healthcar, and the rest have below average ratings.<BR><BR>Return Snapshot: Medplus Health has the highest 1-year return at 38.34%, while Aditya Vision has the lowest at -19.70%. Entero Healthcar's 1-year return is 4.75%, which is higher than Aditya Vision's but lower than Medplus Health's. Additionally, Khemani Distrib. is the only peer with a positive six-month return, while the rest have negative returns.

View full answer

What does Entero Healthcar do?

17-Jul-2025

Entero Healthcare Solutions Ltd is a mid-cap retail company, incorporated in 2018, with recent net sales of ₹13,391 Cr and a net profit of ₹257 Cr for the quarter ending March 2025. Key financial metrics include a P/E ratio of 55.00 and a market cap of ₹5,468 Cr.

Overview:<BR>Entero Healthcare Solutions Ltd operates in the retailing industry and is categorized as a mid-cap company.<BR><BR>History:<BR>The company was incorporated in 2018 as Entero Healthcare Solutions Private Limited and later converted into a public limited company, changing its name to Entero Healthcare Solutions Ltd. The latest quarterly results report net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 13,391 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 257 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 5,468 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 55.00 <BR>Industry P/E: 29 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.04 <BR>Return on Equity: 5.50% <BR>Price to Book: 3.15 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

View full answer

Who are the top shareholders of the Entero Healthcar?

17-Jul-2025

The top shareholders of Entero Healthcare include Orbimed Asia III Mauritius Limited with 38.01%, 70 foreign institutional investors holding 19.92%, and Surbhi Singh of the Prasid Uno Family Trust with 10.46%. Additionally, mutual funds hold 6.09%, while individual investors own 5.41% of the company.

The top shareholders of Entero Healthcare include several key players. The majority of the shares are held by promoters, with Orbimed Asia III Mauritius Limited being the largest individual promoter, holding 38.01%. Additionally, there are 70 foreign institutional investors (FIIs) collectively holding 19.92% of the shares. Mutual funds have a presence as well, with 7 schemes holding 6.09%. Among public shareholders, Surbhi Singh, representing the Prasid Uno Family Trust, is the largest, holding 10.46%. Individual investors collectively own 5.41% of the company.

View full answer

How big is Entero Healthcar?

24-Jul-2025

As of 24th July, Entero Healthcare Solutions Ltd has a market capitalization of 5,220.00 Cr, with net sales of 5,095.79 Cr and a net profit of 94.83 Cr reported for the latest four quarters. The company also has shareholder's funds of 1,638.06 Cr and total assets of 2,325.95 Cr for the annual period ending March 2024.

As of 24th July, Entero Healthcare Solutions Ltd has a market capitalization of 5,220.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, Entero Healthcare reported net sales of 5,095.79 Cr and a net profit of 94.83 Cr.<BR><BR>For the latest annual period ending March 2024, the company reported shareholder's funds of 1,638.06 Cr and total assets of 2,325.95 Cr.

View full answer

How has been the historical performance of Entero Healthcar?

15-Nov-2025

Entero Healthcar has shown significant growth over the past five years, with net sales increasing from 1,779.74 Cr in March 2021 to 5,095.78 Cr in March 2025, and profit after tax turning positive at 107.43 Cr. The company has improved its operating profit and total assets while achieving a net cash inflow from investing activities in March 2025.

Answer:<BR>The historical performance of Entero Healthcar shows significant growth over the past five years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Entero Healthcar's net sales have increased from 1,779.74 Cr in March 2021 to 5,095.78 Cr in March 2025, reflecting a strong upward trend. Total operating income has followed a similar trajectory, rising from 1,779.74 Cr to 5,095.78 Cr during the same period. The company's total expenditure, excluding depreciation, has also grown, reaching 4,924.23 Cr in March 2025, up from 1,758.19 Cr in March 2021. Operating profit, excluding other income, has improved significantly, moving from 21.55 Cr in March 2021 to 171.55 Cr in March 2025. This growth in operating profit has contributed to a profit before tax of 138.74 Cr in March 2025, a substantial increase from the losses recorded in previous years. The profit after tax has turned positive, reaching 107.43 Cr in March 2025, compared to losses in earlier years. The company's total assets have increased from 748.97 Cr in March 2020 to 2,688.21 Cr in March 2025, while total liabilities have also risen, from 748.97 Cr to 2,688.21 Cr. Cash flow from operating activities has shown negative trends, but cash flow from investing activities has turned positive in March 2025, indicating a net cash inflow of 81.00 Cr. Overall, Entero Healthcar has demonstrated a remarkable recovery and growth in its financial performance over the past five years.

View full answer

Is Entero Healthcar overvalued or undervalued?

17-Nov-2025

As of November 14, 2025, Entero Healthcare is considered very attractive and undervalued with a PE ratio of 44.13 and a PEG ratio of 0.31, despite a challenging year-to-date return of -20.6%, indicating strong growth potential compared to its peers.

As of 14 November 2025, Entero Healthcare has moved from an attractive to a very attractive valuation grade. The company is currently considered undervalued, with a PE ratio of 44.13, an EV to EBITDA of 23.43, and a PEG ratio of 0.31, indicating strong growth potential relative to its price. <BR><BR>In comparison to its peers, Entero's PE ratio significantly exceeds that of TCS at 22.34 and Infosys at 22.19, while its EV to EBITDA is higher than TCS's 15.7 but lower than that of LTI Mindtree at 23.98. Despite a challenging year with a year-to-date return of -20.6% compared to the Sensex's 8.22%, Entero Healthcare's strong valuation metrics suggest it remains an attractive investment opportunity in the retailing sector.

View full answer

Is Entero Healthcar technically bullish or bearish?

20-Nov-2025

As of November 19, 2025, Entero Healthcare's technical trend is bearish with moderate strength, indicated by bearish MACD, Bollinger Bands, moving averages, and KST, despite mixed signals from Dow Theory.

As of 19 November 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include a bearish MACD on the weekly timeframe, bearish signals from Bollinger Bands on both weekly and monthly timeframes, and bearish moving averages on the daily timeframe. Additionally, the KST is bearish on the weekly, and the OBV shows a mildly bearish trend on the monthly. The Dow Theory reflects a mildly bullish stance on the weekly but is mildly bearish on the monthly, indicating mixed signals. Overall, the prevailing bearish indicators suggest a negative outlook for Entero Healthcare.

View full answer

When is the next results date for Entero Healthcare Solutions Ltd?

04-Feb-2026

The next results date for Entero Healthcare Solutions Ltd is 12 February 2026.

The next results date for Entero Healthcare Solutions Ltd is scheduled for 12 February 2026.

View full answer

Are Entero Healthcare Solutions Ltd latest results good or bad?

13-Feb-2026

Entero Healthcare Solutions Ltd's latest results show strong revenue growth with record net sales of ₹1,706.52 crores, but a 12.56% decline in net profit and decreasing profit margins raise concerns about profitability, suggesting a cautious outlook for investors.

Entero Healthcare Solutions Ltd's latest results present a mixed picture. On one hand, the company achieved record net sales of ₹1,706.52 crores in Q3 FY26, reflecting a strong 8.63% growth quarter-over-quarter (QoQ) and an impressive 25.57% growth year-over-year (YoY). This indicates robust demand for its pharmaceutical retail services and successful expansion efforts.<BR><BR>However, the consolidated net profit for the same quarter was ₹27.63 crores, which represents a concerning 12.56% decline QoQ, despite an 8.61% increase YoY. This decline raises questions about the company's ability to convert its revenue growth into sustainable profitability. Additionally, the profit after tax (PAT) margin decreased to 1.99%, down from 2.33% in the previous quarter, indicating pressure on profitability.<BR><BR>While the operating margin improved slightly to 3.97%, the overall financial performance suggests that Entero is facing operational challenges, particularly in managing costs and achieving consistent profit growth. The stock has also struggled recently, trading significantly below its 52-week high, which reflects market concerns about its financial stability and future profitability.<BR><BR>In summary, while Entero Healthcare's revenue growth is commendable, the decline in profit and margin pressures indicate that the results are more concerning than positive, warranting a cautious outlook from investors.

View full answer

Should I buy, sell or hold Entero Healthcare Solutions Ltd?

26-Feb-2026

Why is Entero Healthcare Solutions Ltd falling/rising?

17-Mar-2026

As of 16-Mar, Entero Healthcare Solutions Ltd is experiencing a decline in its stock price, currently at 1,001.00, reflecting a total decline of -4.34% over the last six days. The stock has underperformed against the benchmark Sensex and shows a bearish trend, indicating a lack of investor confidence despite some positive long-term growth factors.

As of 16-Mar, Entero Healthcare Solutions Ltd is experiencing a decline in its stock price, currently at 1,001.00, which reflects a change of -9.8 (-0.97%). The stock has been underperforming, having lost value for the last six consecutive days, resulting in a total decline of -4.34% during this period. <BR><BR>In terms of broader performance, the stock has underperformed the benchmark Sensex, with a 1-week return of -2.91% compared to the Sensex's -2.66%. Over the past month, the stock has dropped -9.68%, while the Sensex has decreased by -9.34%. Year-to-date, Entero Healthcare has seen a decline of -2.42%, contrasting with the Sensex's -11.40%. However, the stock has significantly underperformed over the past year, with a return of -14.66% against the Sensex's positive return of +2.27%.<BR><BR>Despite some positive factors, such as a strong ability to service debt and healthy long-term growth in net sales and operating profit, the stock's recent performance indicates a lack of investor confidence. The weighted average price suggests that more volume has been traded closer to the low price, and the stock is trading below its moving averages across various time frames, indicating a bearish trend. Additionally, while there has been a rise in delivery volume, the overall market sentiment appears to be negative, contributing to the stock's decline. <BR><BR>Overall, the combination of recent underperformance, negative returns compared to the market, and a lack of upward momentum in trading suggests that Entero Healthcare Solutions Ltd is currently falling.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Retailing

stock-summary
Market cap

INR 4,837 Cr (Small Cap)

stock-summary
P/E

40.00

stock-summary
Industry P/E

21

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.16

stock-summary
Return on Equity

6.26%

stock-summary
Price to Book

2.70

Revenue and Profits:
Net Sales:
1,707 Cr
(Quarterly Results - Dec 2025)
Net Profit:
28 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
15.73%
0%
15.73%
6 Months
-1.45%
0%
-1.45%
1 Year
-4.5%
0%
-4.5%
2 Years
10.58%
0%
10.58%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Entero Healthcar for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Announcements stock-summary

Announcement under Regulation 30 (LODR)-Change in Management

11-Mar-2026 | Source : BSE

Change in Senior Management Personnel

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

04-Mar-2026 | Source : BSE

Intimation of Schedule of Analyst/Institutional Investor meet to be held on March 11 2026.

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

04-Mar-2026 | Source : BSE

Intimation of Schedule of Analyst/Institutional Investor meet to be held on March 09 2026

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
26.28%
EBIT Growth (5y)
56.53%
EBIT to Interest (avg)
2.61
Debt to EBITDA (avg)
2.54
Net Debt to Equity (avg)
0.16
Sales to Capital Employed (avg)
2.28
Tax Ratio
16.69%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
21.56%
ROCE (avg)
7.73%
ROE (avg)
6.26%

Valuation key factors

Factor
Value
P/E Ratio
40
Industry P/E
21
Price to Book Value
2.70
EV to EBIT
26.29
EV to EBITDA
22.04
EV to Capital Employed
2.46
EV to Sales
0.84
PEG Ratio
1.22
Dividend Yield
NA
ROCE (Latest)
8.59%
ROE (Latest)
6.26%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 8 Schemes (10.25%)

FIIs

Held by 63 FIIs (5.14%)

Promoter with highest holding

Orbimed Asia Iii Mauritius Limited (38.01%)

Highest Public shareholder

Surbi Singhprasad Und Family Trust (10.46%)

Individual Investors Holdings

11.56%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 8.63% vs 11.91% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -12.56% vs 13.67% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,706.52",
          "val2": "1,570.95",
          "chgp": "8.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "67.78",
          "val2": "62.06",
          "chgp": "9.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "14.01",
          "val2": "12.40",
          "chgp": "12.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-8.18",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "27.63",
          "val2": "31.60",
          "chgp": "-12.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "3.97%",
          "val2": "3.95%",
          "chgp": "0.02%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 24.07% vs 26.50% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 35.93% vs 284.34% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,974.77",
          "val2": "2,397.73",
          "chgp": "24.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "112.14",
          "val2": "72.62",
          "chgp": "54.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "23.06",
          "val2": "21.16",
          "chgp": "8.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "59.40",
          "val2": "43.70",
          "chgp": "35.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "3.77%",
          "val2": "3.03%",
          "chgp": "0.74%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 24.61% vs 30.07% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 25.88% vs 280.94% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4,681.29",
          "val2": "3,756.73",
          "chgp": "24.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "179.92",
          "val2": "122.64",
          "chgp": "46.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "37.07",
          "val2": "31.13",
          "chgp": "19.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-8.18",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "87.03",
          "val2": "69.14",
          "chgp": "25.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "3.84%",
          "val2": "3.26%",
          "chgp": "0.58%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 29.92% vs 18.85% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 142.44% vs 438.32% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,095.78",
          "val2": "3,922.31",
          "chgp": "29.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "171.55",
          "val2": "111.85",
          "chgp": "53.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "41.62",
          "val2": "65.68",
          "chgp": "-36.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "94.82",
          "val2": "39.11",
          "chgp": "142.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "3.37%",
          "val2": "2.85%",
          "chgp": "0.52%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
1,706.52
1,570.95
8.63%
Operating Profit (PBDIT) excl Other Income
67.78
62.06
9.22%
Interest
14.01
12.40
12.98%
Exceptional Items
-8.18
0.00
Consolidate Net Profit
27.63
31.60
-12.56%
Operating Profit Margin (Excl OI)
3.97%
3.95%
0.02%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is 8.63% vs 11.91% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -12.56% vs 13.67% in Sep 2025

Half Yearly Results Snapshot (Consolidated) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
2,974.77
2,397.73
24.07%
Operating Profit (PBDIT) excl Other Income
112.14
72.62
54.42%
Interest
23.06
21.16
8.98%
Exceptional Items
0.00
0.00
Consolidate Net Profit
59.40
43.70
35.93%
Operating Profit Margin (Excl OI)
3.77%
3.03%
0.74%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 24.07% vs 26.50% in Sep 2024

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2025 is 35.93% vs 284.34% in Sep 2024

Nine Monthly Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
4,681.29
3,756.73
24.61%
Operating Profit (PBDIT) excl Other Income
179.92
122.64
46.71%
Interest
37.07
31.13
19.08%
Exceptional Items
-8.18
0.00
Consolidate Net Profit
87.03
69.14
25.88%
Operating Profit Margin (Excl OI)
3.84%
3.26%
0.58%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is 24.61% vs 30.07% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2025 is 25.88% vs 280.94% in Dec 2024

Annual Results Snapshot (Consolidated) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
5,095.78
3,922.31
29.92%
Operating Profit (PBDIT) excl Other Income
171.55
111.85
53.38%
Interest
41.62
65.68
-36.63%
Exceptional Items
0.00
0.00
Consolidate Net Profit
94.82
39.11
142.44%
Operating Profit Margin (Excl OI)
3.37%
2.85%
0.52%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 29.92% vs 18.85% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 142.44% vs 438.32% in Mar 2024

stock-summaryCompany CV
About Entero Healthcare Solutions Ltd stock-summary
stock-summary
Entero Healthcare Solutions Ltd
Small Cap
Retailing
Entero Healthcare Solutions Limited was incorporated as `Entero Healthcare Solutions Private Limited' dated January 10, 2018, issued by the Registrar of Companies, Central Registration Centre, at New Delhi. Subsequently, the Company was converted into a public limited company and the name of the Company was changed to `Entero Healthcare Solutions Limited', and a fresh certificate of incorporation dated August 25, 2023, was issued by the RoC.
Company Coordinates stock-summary
Icon
No Company Details Available